Eterna Therapeutics Announces Inaugural Scientific Advisory Board Meeting, Discussed ERNA-101 Preclinical Advances In Ovarian Cancer, Focused On Immune Activation, Tumor Microenvironment, Combination Therapies, And ERNA-102 For Autoimmune Diseases

Some highlights from the meeting include:

• The board discussed the positive preclinical data for ERNA-101 in ovarian cancer, including immune activation, tumor microenvironment interactions, and potential combination strategies. Further studies are planned to optimize dose and route of administration in order to maximize downstream anti-tumor immune responses.
• The board was aligned on further advancing rigorous quality, safety, and efficacy criteria for product consistency, engaging with regulatory agencies, and prioritizing clinical trial design to accelerate the path to first-in-human studies.
• They also highlighted potential combination therapies with CAR-T therapy, MUC16-targeting agents, and other immunomodulatory approaches to enhance treatment efficacy in challenging disease areas.
• Lastly, the board focused on potential therapeutic indications within autoimmune disease for ERNA-102. Additional research will be conducted for further assessment.

Eterna will continue to collaborate with the Scientific Advisory Board and key stakeholders to translate these innovative therapies into impactful clinical practice.